204 related articles for article (PubMed ID: 15693135)
1. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
2. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
DiJoseph JF; Armellino DC; Boghaert ER; Khandke K; Dougher MM; Sridharan L; Kunz A; Hamann PR; Gorovits B; Udata C; Moran JK; Popplewell AG; Stephens S; Frost P; Damle NK
Blood; 2004 Mar; 103(5):1807-14. PubMed ID: 14615373
[TBL] [Abstract][Full Text] [Related]
3. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.
Damle NK; Frost P
Curr Opin Pharmacol; 2003 Aug; 3(4):386-90. PubMed ID: 12901947
[TBL] [Abstract][Full Text] [Related]
4. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
DiJoseph JF; Goad ME; Dougher MM; Boghaert ER; Kunz A; Hamann PR; Damle NK
Clin Cancer Res; 2004 Dec; 10(24):8620-9. PubMed ID: 15623646
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Tuscano JM; O'Donnell RT; Miers LA; Kroger LA; Kukis DL; Lamborn KR; Tedder TF; DeNardo GL
Blood; 2003 May; 101(9):3641-7. PubMed ID: 12511412
[TBL] [Abstract][Full Text] [Related]
6. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
[TBL] [Abstract][Full Text] [Related]
8. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy.
Boghaert ER; Khandke K; Sridharan L; Armellino D; Dougher M; Dijoseph JF; Kunz A; Hamann PR; Sridharan A; Jones S; Discafani C; Damle NK
Int J Oncol; 2006 Mar; 28(3):675-84. PubMed ID: 16465373
[TBL] [Abstract][Full Text] [Related]
9. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.
Damle NK
Expert Opin Biol Ther; 2004 Sep; 4(9):1445-52. PubMed ID: 15335312
[TBL] [Abstract][Full Text] [Related]
10. CD22-directed monoclonal antibody therapy for lymphoma.
Siegel AB; Goldenberg DM; Cesano A; Coleman M; Leonard JP
Semin Oncol; 2003 Aug; 30(4):457-64. PubMed ID: 12939714
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
12. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
13. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.
Dijoseph JF; Dougher MM; Armellino DC; Evans DY; Damle NK
Leukemia; 2007 Nov; 21(11):2240-5. PubMed ID: 17657218
[TBL] [Abstract][Full Text] [Related]
15. Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand.
Engel P; Wagner N; Miller AS; Tedder TF
J Exp Med; 1995 Apr; 181(4):1581-6. PubMed ID: 7535343
[TBL] [Abstract][Full Text] [Related]
16. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I
Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166
[TBL] [Abstract][Full Text] [Related]
17. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
Ho M; Kreitman RJ; Onda M; Pastan I
J Biol Chem; 2005 Jan; 280(1):607-17. PubMed ID: 15491997
[TBL] [Abstract][Full Text] [Related]
18. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes.
Engel P; Nojima Y; Rothstein D; Zhou LJ; Wilson GL; Kehrl JH; Tedder TF
J Immunol; 1993 Jun; 150(11):4719-32. PubMed ID: 7684411
[TBL] [Abstract][Full Text] [Related]
19. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
Newton DL; Hansen HJ; Liu H; Ruby D; Iordanov MS; Magun BE; Goldenberg DM; Rybak SM
Crit Rev Oncol Hematol; 2001; 39(1-2):79-86. PubMed ID: 11418304
[TBL] [Abstract][Full Text] [Related]
20. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]